(Reuters Health) – In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more, according to results from a mid-stage study presented Sunday.
The 76 study participants, who ranged in age from 8 to 49 …
Source: Channel News Asia
Experimental drug delays type 1 diabetes onset in mid-stage trial